IGFL2 and nonpapillary renal cell carcinoma: Overall, our study identifies IGFL2-AS1 mediated AR signaling as the key to bridge VM formation and pazopanib resistance and targeting this signaling axis could overcome resistance of ccRCC cells to pazopanib treatment.